-transparent.png){kind=logo}
Myeloid derived suppressor cells (MDSCs) are defined in mice on the basis of CD11b and Gr-1 marker expression and the functional ability to inhibit T lymphocyte activation. Nevertheless the term 'heterogeneous' remains the first, informal feature commonly attributed to this population. It is clear that CD11b(+)Gr-1(+) cells are part of a myeloid macropopulation, which comprises at least two subsets of polymorphonuclear and monocytic cells with different immunosuppressive properties. While recent literature shows substantial agreement on the immunoregulatory property of the monocytic MDSC subset, there is still contrasting evidence on the role of the granulocytic fraction. Moreover, this dichotomy holds true for human MDSCs. We attempt here to summarize conflicting findings in the field and provide some possible, unifying explanations.
Elisa Peranzoni, and
Serena Zilio, and
Ilaria Marigo, and
Luigi Dolcetti, and
Paola Zanovello, and
Susanna Mandruzzato, and
Vincenzo Bronte
June 2014,
Annals of the New York Academy of Sciences,
Elisa Peranzoni, and
Serena Zilio, and
Ilaria Marigo, and
Luigi Dolcetti, and
Paola Zanovello, and
Susanna Mandruzzato, and
Vincenzo Bronte
March 2024,
Journal of leukocyte biology,
Elisa Peranzoni, and
Serena Zilio, and
Ilaria Marigo, and
Luigi Dolcetti, and
Paola Zanovello, and
Susanna Mandruzzato, and
Vincenzo Bronte
December 2010,
European journal of immunology,
Elisa Peranzoni, and
Serena Zilio, and
Ilaria Marigo, and
Luigi Dolcetti, and
Paola Zanovello, and
Susanna Mandruzzato, and
Vincenzo Bronte
March 2015,
Oncoimmunology,
Elisa Peranzoni, and
Serena Zilio, and
Ilaria Marigo, and
Luigi Dolcetti, and
Paola Zanovello, and
Susanna Mandruzzato, and
Vincenzo Bronte
December 2018,
Infection and immunity,
Elisa Peranzoni, and
Serena Zilio, and
Ilaria Marigo, and
Luigi Dolcetti, and
Paola Zanovello, and
Susanna Mandruzzato, and
Vincenzo Bronte
May 2015,
Cellular immunology,
Elisa Peranzoni, and
Serena Zilio, and
Ilaria Marigo, and
Luigi Dolcetti, and
Paola Zanovello, and
Susanna Mandruzzato, and
Vincenzo Bronte
November 2021,
Leukemia,
Elisa Peranzoni, and
Serena Zilio, and
Ilaria Marigo, and
Luigi Dolcetti, and
Paola Zanovello, and
Susanna Mandruzzato, and
Vincenzo Bronte
January 2021,
Journal of cancer research and therapeutics,
Elisa Peranzoni, and
Serena Zilio, and
Ilaria Marigo, and
Luigi Dolcetti, and
Paola Zanovello, and
Susanna Mandruzzato, and
Vincenzo Bronte
January 2017,
Oncoscience,
Elisa Peranzoni, and
Serena Zilio, and
Ilaria Marigo, and
Luigi Dolcetti, and
Paola Zanovello, and
Susanna Mandruzzato, and
Vincenzo Bronte
July 2009,
International immunopharmacology,
